244 related articles for article (PubMed ID: 27650859)
1. Challenges in Oral Lipid-lowering Therapy: Position Document of the Spanish Society of Cardiology.
Anguita Sánchez M; Castro Conde A; Cordero Fort A; García-Moll Marimón X; Gómez Doblas JJ; González-Juanatey JR; Lidón Corbi RM; López-Sendón JL; Mostaza Prieto J; Rodríguez Padial L
Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1083-1087. PubMed ID: 27650859
[TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.
Ortega Martínez de Victoria E
Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604
[No Abstract] [Full Text] [Related]
3. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
4. Combined lipid-lowering therapy.
Karásek D
Vnitr Lek; 2019; 64(12):1177-1184. PubMed ID: 30704254
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of lipid lowering with PCSK9 inhibitors in patients with familial hypercholesterolemia: Methodological aspects.
Wisløff T; Mundal LJ; Retterstøl K; Igland J; Kristiansen IS
Atherosclerosis; 2019 Aug; 287():140-146. PubMed ID: 31280039
[TBL] [Abstract][Full Text] [Related]
6. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
Blom DJ; Dent R; Castro RC; Toth PP
Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
[TBL] [Abstract][Full Text] [Related]
7. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
8. [Up to date lipid lowering treatment].
Paragh G; Karádi I
Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
[TBL] [Abstract][Full Text] [Related]
9. Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors.
Shahreyar M; Salem SA; Nayyar M; George LK; Garg N; Koshy SKG
J Am Board Fam Med; 2018; 31(4):628-634. PubMed ID: 29986989
[TBL] [Abstract][Full Text] [Related]
10. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
[TBL] [Abstract][Full Text] [Related]
11. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials.
Ridker PM; Amarenco P; Brunell R; Glynn RJ; Jukema JW; Kastelein JJ; Koenig W; Nissen S; Revkin J; Santos RD; Schwartz PF; Yunis C; Tardif JC;
Am Heart J; 2016 Aug; 178():135-44. PubMed ID: 27502861
[TBL] [Abstract][Full Text] [Related]
12. What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management?
Stein EA
Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):97-105. PubMed ID: 26859553
[TBL] [Abstract][Full Text] [Related]
13. Evolocumab: A Review in Hyperlipidemia.
Keating GM
Am J Cardiovasc Drugs; 2016 Feb; 16(1):67-78. PubMed ID: 26643308
[TBL] [Abstract][Full Text] [Related]
14. PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook.
Di Bartolo B; Scherer DJ; Brown A; Psaltis PJ; Nicholls SJ
BioDrugs; 2017 Jun; 31(3):167-174. PubMed ID: 28424973
[TBL] [Abstract][Full Text] [Related]
15. Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance.
Koskinas K; Wilhelm M; Windecker S
Swiss Med Wkly; 2016; 146():w14333. PubMed ID: 27400448
[TBL] [Abstract][Full Text] [Related]
16. Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Sociey of Arteriosclerosis (SEA), 2019.
Ascaso JF; Civeira F; Guijarro C; López Miranda J; Masana L; Mostaza JM; Pedro-Botet J; Pintó X; Valdivielso P
Clin Investig Arterioscler; 2019; 31(3):128-139. PubMed ID: 31130361
[TBL] [Abstract][Full Text] [Related]
17. New Therapies in the Treatment of High Cholesterol: An Argument to Return to Goal-Based Lipid Guidelines.
Shrank WH; Barlow JF; Brennan TA
JAMA; 2015 Oct; 314(14):1443-4. PubMed ID: 26258765
[No Abstract] [Full Text] [Related]
18. [Effective LDL cholesterol reduction for high risk patients].
Einecke D
MMW Fortschr Med; 2016 Apr; 158(8):84. PubMed ID: 27116175
[No Abstract] [Full Text] [Related]
19. Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders.
Gupta S
Vasc Health Risk Manag; 2016; 12():421-433. PubMed ID: 27877050
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center.
Shah P; Glueck CJ; Jetty V; Goldenberg N; Rothschild M; Riaz R; Duhon G; Wang P
Lipids Health Dis; 2016 Aug; 15(1):132. PubMed ID: 27538393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
